Organization
Qlucore Expands Into Bladder Cancer Diagnostics With Lund University Partnership
The company expects that this work to develop and validate classifier models for bladder cancer will lead to a CE mark for its Qlucore Diagnostics software platform.
Seagen Going After Tukysa, Herceptin Combo Approval in HER2-Positive Colorectal Cancer
The company plans to seek accelerated approval for the regimen after seeing a 38 percent objective response rate in the MOUNTAINEER trial.
The lead investigators have also spun out a company, Isabl, aiming to make the approach available to the broader community.
The agency acknowledges its staff can't keep up with the volume of cell and gene therapy products and is looking to PDUFA VII for additional funds.Â
Prostate Cancer UK Funds Study of Angle's Parsortix Liquid Biopsy Test in Prostate Cancer
The trial at Barts Cancer Institute will follow 200 prostate cancer patients over five years and gauge if the CTC test can identify who will recur after surgery.